Proximity proteome mapping reveals PD-L1-dependent pathways disrupted by anti-PD-L1 antibody specifically in EGFR-mutant lung cancer cells

BACKGROUND: PD-L1, a transmembrane ligand for immune checkpoint receptor PD1, has been successfully targeted to activate an anti-tumor immune response in a variety of solid tumors, including non-small cell lung cancer (NSCLC). Despite the success of targeting PD-L1, only about 20% of patients achiev...

Descripción completa

Detalles Bibliográficos
Autores principales: Letian, Anudari, Lemma, Eyoel Yemanaberhan, Cavaliere, Paola, Dephoure, Noah, Altorki, Nasser K., McGraw, Timothy E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010028/
https://www.ncbi.nlm.nih.gov/pubmed/36915197
http://dx.doi.org/10.1186/s12964-023-01084-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010028/
https://www.ncbi.nlm.nih.gov/pubmed/36915197
http://dx.doi.org/10.1186/s12964-023-01084-6

Ejemplares similares